Medical diagnostic company, Proteomics International has been awarded a $100,000 funding voucher to support the Western Australian manufacture of its PromarkerD predictive test for diabetic kidney disease and its other diagnostic blood tests. The company plans to use the funds to establish additional quality control processes for production of an immunoassay version of its PromarkerD test.
The funding falls under a medical technology and pharmaceutical ‘Manufacturing Voucher Program’ run by the MTPConnect WA Life Sciences Innovation Hub. The body is an independent and non-profit organisation co-funded by the University of Western Australia and the Western Australia Government’s ‘New Industries Fund’.
Proteomics has secured the voucher for its nine-month research project titled “Manufacturing the next generation in vitro diagnostic device to predict diabetic kidney disease”.
The company will match the $100,000 contribution from MTP Connect.
According to Proteomics, PromarkerD is the world’s only test for predicting the onset of kidney disease in type-two diabetes patients before clinical symptoms appear. It says the test can predict a decline in renal function up to four years in advance.
Proteomics is also utilising its proprietary Promarker technology to create a series of other novel diagnostic tests, including tests for endometriosis, asthma and oesophageal cancer just to name a few.
Under the research project, the company will establish Western Australia based manufacturing quality control processes for its PromarkerD test.
Proteomics believes the initiative will support the future large-scale production of PromarkerD for Australian and Southeast Asian markets. It says the venture could help develop its manufacturing know-how to make PromarkerD more readily available in both regions.
According to the company, the project could potentially boost future sales of the test in Australia and Southeast Asia.
The initiative may also pave the way for Proteomics to launch the other diagnostic tests it is currently developing.
Australian medical device companies who want to manufacture diagnostic tests of this kind currently have to partner with businesses overseas to meet globally-recognised standards. This project will build expertise here in Western Australia, ensuring more Australian intellectual property remains onshore, creating speciality jobs, and attracting local and international talent
Proteomics appears to be growing into a key player in the fight against diabetic kidney disease. A $100,000 contribution toward local manufacture of PromarkerD will likely be a welcome boost to the company’s commercialisation push of its diagnostic tests.
Is your ASX-listed company doing something interesting? Contact: email@example.com